In preclinical studies, a single dose of 211At-labeled mAbs targeting CD123 (1.48 MBq) decreased tumor burden and significantly prolonged survival in MOLM-13 AML xenograft models [87]. This evidence concerns the gene IL3RA and acute myeloid leukemia.